8-KLeadership Changes

Guardant Health, Inc. 8-K Report, Executive Changes (May 31, 2024)

Filed May 31, 2024For Securities:GH

Summary

Guardant Health, Inc. (GH) filed an 8-K on May 31, 2024, detailing amendments to its Executive Severance Plan. These changes, effective May 24, 2024, primarily impact the severance packages for executive employees, particularly in scenarios involving termination without cause or for good reason, and in connection with a change in control. The amendments standardize severance benefits, with increased payouts and accelerated equity vesting for Co-CEOs Helmy Eltoukhy and AmirAli Talasaz, especially during a change in control event. The revised plan provides for enhanced severance benefits, including extended salary and COBRA payments, and accelerated vesting of equity awards. Notably, these enhanced benefits are more generous for Co-CEOs, with provisions for 18 to 24 months of salary and COBRA payments, and full or significantly accelerated vesting of their equity awards under specific termination conditions and change in control scenarios. These updates reflect a strategic review and aim to align executive compensation and retention with potential future corporate events.

Key Highlights

  • 1Guardant Health amended its Executive Severance Plan, effective May 24, 2024, affecting all executive employees.
  • 2Severance benefits are differentiated based on termination type (without cause or for good reason) and proximity to a change in control (CIC).
  • 3For a 'Non-CIC Termination' (outside 3 months pre/1 year post-CIC), executives receive 12 months base salary, pro-rated bonus, and 12 months COBRA.
  • 4For a 'CIC Termination' (within 3 months pre/1 year post-CIC), executives receive 18 months base salary (24 months for Co-CEOs), full bonus, and 18 months COBRA (24 months for Co-CEOs).
  • 5In a CIC Termination, all outstanding equity awards for executives vest in full, with performance goals met at the greater of target or actual achievement.
  • 6Co-CEOs Helmy Eltoukhy and AmirAli Talasaz have specific provisions, including their equity awards (RSUs and PSUs) being eligible for accelerated vesting, often at higher levels or with specific performance conditions tied to change in control dates.
  • 7Specific clauses detail enhanced vesting for Co-CEO equity awards, particularly for 2024 long-term RSU and PSU awards, with vesting accelerating if terminations occur before December 31, 2025, under certain conditions.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose amendments to Guardant Health's Executive Severance Plan. These amendments update the severance packages offered to executive employees, particularly concerning termination events and changes in control.

For a standard termination without cause or for good reason (Non-CIC Termination), executives receive 12 months of base salary, a pro-rated bonus, and 12 months of COBRA payments. In contrast, for a termination occurring around a change in control (CIC Termination), executives receive 18 months of base salary (24 months for Co-CEOs), the full annual bonus, 18 months of COBRA (24 months for Co-CEOs), and accelerated vesting of all outstanding equity awards.

Yes, the Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, have enhanced severance terms. They are eligible for 24 months of base salary and COBRA payments in the event of a CIC Termination. Their equity awards, including RSUs and PSUs, also have specific accelerated vesting provisions, which are particularly favorable if a termination occurs before the end of 2025 or in connection with a change in control, with enhanced performance targets for vesting.

The CIC provisions are significant as they indicate enhanced compensation packages designed to retain and incentivize key executives during periods of potential acquisition or significant corporate restructuring. The accelerated equity vesting ensures executives are financially compensated if their employment is terminated shortly before or after such an event, potentially smoothing the transition for stakeholders and aligning executive interests with transaction outcomes.